AIDS

Skip Navigation LinksHome > January 2, 2008 - Volume 22 - Issue 1 > Interruptions of tenofovir/emtricitabine-based antiretrovira...
AIDS:
doi: 10.1097/QAD.0b013e3282f303bf
Research Letters

Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection

Nüesch, Retoa,b; Ananworanich, Jintanata; Srasuebkul, Preeyapornc; Chetchotisakd, Ploenchand; Prasithsirikul, Wisite; Klinbuayam, Wiratf; Mahanontharit, Apichaa; Jupimai, Thidarata; Ruxrungtham, Kiata; Hirschel, Bernardg

Collapse Box

Abstract

Thai patients enrolled in STACCATO with HIV/hepatitis B virus (HBV) co-infection and tenofovir/emtricitabine-based antiretroviral therapy (ART) were randomly assigned to continuous treatment or CD4 cell count-guided interruptions. HBV replication was suppressed below detection in 15/16 patients. Structured treatment interruption increased transaminases and HBV viraemia in five of six patients; one flare was severe. Conversion to anti-hepatitis Be occurred with continuous treatment only. Tenofovir/emtricitabine-containing ART is highly effective in controlling chronic HIV/HBV co-infection but treatment should not be interrupted.

© 2008 Lippincott Williams & Wilkins, Inc.

Login

Article Level Metrics